{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T03:53:49Z","timestamp":1777780429762,"version":"3.51.4"},"reference-count":91,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.beha.2018.07.008","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T00:24:02Z","timestamp":1532478242000},"page":"251-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["An update in treating transformed lymphoma"],"prefix":"10.1016","volume":"31","author":[{"given":"James","family":"Godfrey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Leukam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9893-4949","authenticated-orcid":false,"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"33","key":"10.1016\/j.beha.2018.07.008_bib1","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1200\/JCO.2006.07.5671","article-title":"Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis","volume":"24","author":"Ghesquieres","year":"2006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"17","key":"10.1016\/j.beha.2018.07.008_bib2","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2018.07.008_bib3","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","article-title":"Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients","volume":"15","author":"Bastion","year":"1997","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.beha.2018.07.008_bib4","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/Mayo clinic specialized program of Research excellence molecular Epidemiology resource","volume":"31","author":"Link","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2018.07.008_bib5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdn657","article-title":"The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)","volume":"20","author":"Noy","year":"2009","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"21","key":"10.1016\/j.beha.2018.07.008_bib6","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","article-title":"Intensity of 18 fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma","volume":"23","author":"Schoder","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2018.07.008_bib7","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non\u2013cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2018.07.008_bib8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3324\/haematol.12013","article-title":"Investigation of FDG-PET\/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma","volume":"93","author":"Bodet-Milin","year":"2008","journal-title":"Haematologica"},{"issue":"364","key":"10.1016\/j.beha.2018.07.008_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"issue":"32","key":"10.1016\/j.beha.2018.07.008_bib10","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2018.07.008_bib11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood-2017-03-691345","article-title":"Can histologic transformation of follicular lymphoma be predicted and prevented?","volume":"130","author":"Kridel","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2018.07.008_bib12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/annonc\/mds433","article-title":"Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy","volume":"24","author":"Bains","year":"2013","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"7","key":"10.1016\/j.beha.2018.07.008_bib13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","article-title":"Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)","volume":"126","author":"Wagner-Johnston","year":"2015","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2018.07.008_bib14","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-Cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2018.07.008_bib15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2141.2012.09054.x","article-title":"Incidence, risk factors and outcome of histological transformation in follicular lymphoma","volume":"157","author":"Conconi","year":"2012","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.beha.2018.07.008_bib16","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.beha.2018.07.008_bib17","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood-2015-06-649905","article-title":"Cell of origin of transformed follicular lymphoma","volume":"126","author":"Kridel","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2018.07.008_bib18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.beha.2018.07.008_bib19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.14201","article-title":"The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era","volume":"175","author":"Blaker","year":"2016","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2018.07.008_bib20","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1158\/1078-0432.CCR-13-2367","article-title":"Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma","volume":"20","author":"Smeltzer","year":"2014","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.beha.2018.07.008_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2008-02-140616","article-title":"Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances","volume":"113","author":"Cheung","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2018.07.008_bib22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1056\/NEJM198701083160204","article-title":"Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer","volume":"316","author":"Yunis","year":"1987","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.beha.2018.07.008_bib23","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1182\/blood-2010-03-272278","article-title":"Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones","volume":"116","author":"Eide","year":"2010","journal-title":"Blood"},{"issue":"9759","key":"10.1016\/j.beha.2018.07.008_bib24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2018.07.008_bib25","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/asheducation-2015.1.625","article-title":"Treatment of patients with transformed lymphoma","volume":"2015","author":"Montoto","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.beha.2018.07.008_bib26","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/ajh.23939","article-title":"Hodgkin transformation of chronic lymphocytic leukemia: incidence, outcomes, and comparison to de novo Hodgkin lymphoma","volume":"90","author":"Parikh","year":"2015","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.beha.2018.07.008_bib27","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11899-014-0223-4","article-title":"Risk factors for Richter syndrome in chronic lymphocytic leukemia","volume":"9","author":"Parikh","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"issue":"12","key":"10.1016\/j.beha.2018.07.008_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.beha.2018.07.008_bib29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/(SICI)1098-2264(200001)27:1<85::AID-GCC11>3.0.CO;2-9","article-title":"Interphase FISH detection of BCL2 rearrangement in follicular lymphoma using breakpoint-flanking probes","volume":"27","author":"Vaandrager","year":"2000","journal-title":"Genes Chromosomes Cancer"},{"issue":"4","key":"10.1016\/j.beha.2018.07.008_bib30","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1182\/blood-2009-01-198580","article-title":"Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations","volume":"114","author":"Leich","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2018.07.008_bib31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/leu.2017.270","article-title":"Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing","volume":"32","author":"Zamo","year":"2018","journal-title":"Leukemia"},{"issue":"4720","key":"10.1016\/j.beha.2018.07.008_bib32","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1126\/science.3929382","article-title":"The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining","volume":"229","author":"Tsujimoto","year":"1985","journal-title":"Science (New York, NY)"},{"issue":"6","key":"10.1016\/j.beha.2018.07.008_bib33","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.cell.2008.10.035","article-title":"Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity","volume":"135","author":"Tsai","year":"2008","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.beha.2018.07.008_bib34","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1200\/JCO.1996.14.4.1333","article-title":"BCL-2\/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases","volume":"14","author":"Dolken","year":"1996","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2018.07.008_bib35","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.beha.2018.07.008_bib36","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"Beguelin","year":"2013","journal-title":"Canc Cell"},{"issue":"10","key":"10.1016\/j.beha.2018.07.008_bib37","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/nm.3943","article-title":"The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development","volume":"21","author":"Ortega-Molina","year":"2015","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.beha.2018.07.008_bib38","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/ng.3473","article-title":"Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma","volume":"48","author":"Okosun","year":"2016","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.beha.2018.07.008_bib39","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1046\/j.1365-2559.2002.01506.x","article-title":"Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma","volume":"41","author":"Moller","year":"2002","journal-title":"Histopathology"},{"issue":"7","key":"10.1016\/j.beha.2018.07.008_bib40","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood.V82.7.1994.1994","article-title":"p53 mutation is associated with progression in follicular lymphomas","volume":"82","author":"Sander","year":"1993","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2018.07.008_bib41","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood.V82.8.2289.2289","article-title":"p53 mutations are associated with histologic transformation of follicular lymphoma","volume":"82","author":"Lo Coco","year":"1993","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2018.07.008_bib42","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1182\/blood-2013-05-500595","article-title":"Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma","volume":"123","author":"Bouska","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2018.07.008_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gad.1161904","article-title":"The generation of antibody diversity through somatic hypermutation and class switch recombination","volume":"18","author":"Li","year":"2004","journal-title":"Gene Dev"},{"issue":"6844","key":"10.1016\/j.beha.2018.07.008_bib44","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/35085588","article-title":"Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas","volume":"412","author":"Pasqualucci","year":"2001","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.beha.2018.07.008_bib45","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/01.LAB.0000053913.85892.E9","article-title":"Gene expression profile of serial samples of transformed B-cell lymphomas","volume":"83","author":"de Vos","year":"2003","journal-title":"Lab Investig J Techn Methods Pathol"},{"issue":"2","key":"10.1016\/j.beha.2018.07.008_bib46","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/leu.2014.209","article-title":"Genomic and epigenomic co-evolution in follicular lymphomas","volume":"29","author":"Loeffler","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2018.07.008_bib47","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/MOH.0000000000000255","article-title":"The routes for transformation of follicular lymphoma","volume":"23","author":"Okosun","year":"2016","journal-title":"Curr Opin Hematol"},{"issue":"32","key":"10.1016\/j.beha.2018.07.008_bib48","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2018.07.008_bib49","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00277-017-3218-0","article-title":"The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database","volume":"97","author":"Janikova","year":"2018","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.beha.2018.07.008_bib50","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.beha.2018.07.008_bib51","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12570","article-title":"Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database","volume":"163","author":"Ban-Hoefen","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.beha.2018.07.008_bib52","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/bjh.14831","article-title":"Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group","volume":"178","author":"Alonso-Alvarez","year":"2017","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.beha.2018.07.008_bib53","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1080\/10428194.2016.1265114","article-title":"Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013","volume":"58","author":"Gleeson","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.beha.2018.07.008_bib54","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2014-04-516815","article-title":"Transformed follicular non-Hodgkin lymphoma","volume":"125","author":"Casulo","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2018.07.008_bib55","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00277-017-3151-2","article-title":"Transformed follicular lymphoma","volume":"97","author":"Fischer","year":"2018","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.beha.2018.07.008_bib56","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/annonc\/mdu537","article-title":"Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation","volume":"26","author":"Madsen","year":"2015","journal-title":"Ann Oncol"},{"issue":"31","key":"10.1016\/j.beha.2018.07.008_bib57","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2018.07.008_bib58","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood-2015-01-622084","article-title":"Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12","volume":"126","author":"Kuruvilla","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2018.07.008_bib59","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.bbmt.2014.03.014","article-title":"Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma","volume":"20","author":"Wirk","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.beha.2018.07.008_bib60","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","article-title":"Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma","volume":"27","author":"Thomson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2018.07.008_bib61","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma","volume":"26","author":"Rezvani","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2018.07.008_bib62","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.2012.44.0693","article-title":"Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group","volume":"31","author":"Villa","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2018.07.008_bib63","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000449031","article-title":"Outcome comparison of allogeneic versus autologous stem cell transplantation in transformed low-grade lymphoid malignancies: a systematic review and pooled analysis of comparative studies","volume":"136","author":"Yun","year":"2016","journal-title":"Acta Haematol"},{"issue":"12","key":"10.1016\/j.beha.2018.07.008_bib64","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2018.07.008_bib65","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","article-title":"IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution","volume":"31","author":"Mao","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"15","key":"10.1016\/j.beha.2018.07.008_bib66","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2018.07.008_bib67","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/cncr.11238","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"issue":"25","key":"10.1016\/j.beha.2018.07.008_bib68","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.beha.2018.07.008_bib69","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2018.07.008_bib70","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/cncr.30596","article-title":"Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.beha.2018.07.008_bib71","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2018.07.008_bib72","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ejh.12474","article-title":"Platinum and high-dose cytarabine-based regimens are efficient in ultra high\/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study","volume":"95","author":"Durot","year":"2015","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.beha.2018.07.008_bib73","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.23841","article-title":"Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"89","author":"Langerbeins","year":"2014","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.beha.2018.07.008_bib74","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.15035","article-title":"A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers","year":"2018","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.beha.2018.07.008_bib75","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","volume":"30","author":"Cwynarski","year":"2012","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.beha.2018.07.008_bib76","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","article-title":"Biology and treatment of Richter syndrome","volume":"131","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2018.07.008_bib77","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood-2014-12-610782","article-title":"The efficacy of ibrutinib in the treatment of Richter syndrome","volume":"125","author":"Tsang","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2018.07.008_bib78","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-Human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.beha.2018.07.008_bib79","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2018.07.008_bib80","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-0609.2012.01787.x","article-title":"Double-hit BCL2\/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience","volume":"89","author":"Pedersen","year":"2012","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2018.07.008_bib81","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2018.07.008_bib82","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.beha.2018.07.008_bib83","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2018.07.008_bib84","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2018.07.008_bib85","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1200\/JCO.2016.68.2740","article-title":"Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation","volume":"35","author":"Herrera","year":"2017","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.beha.2018.07.008_bib86","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.beha.2018.07.008_bib87","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.beha.2018.07.008_bib88","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR t-cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2018.07.008_bib89","first-page":"130","article-title":"Primary analysis of JULIET: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma","author":"Schuster","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.008_bib90","first-page":"130","article-title":"High durable CR rates in relapsed\/refractory (R\/R) aggressive B-NHL treated with the CD19-directed CAR-t cell product JCAR017 (TRANSCEND NHL 001): defined composition allows for dose-finding and definition of pivotal cohort","author":"Abramson","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2018.07.008_bib91","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.beha.2018.04.001","article-title":"CAR T cell therapy for B-cell lymphomas","volume":"31","author":"Chavez","year":"2018","journal-title":"Best Pract Res Clin Haematol"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T03:14:03Z","timestamp":1571627643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692618300537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1521692618300537"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2018.07.008","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An update in treating transformed lymphoma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2018.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}